Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cary O Harding

Showing results (71-80 of 113) with videos related to

Pageof 12
Sort By:
Journal of Inherited Metabolic Disease|March 10, 2018
Tetrahydrobiopterin treatment reduces brain L-Phe but only partially improves serotonin in hyperphenylalaninemic ENU1/2 miceTanja Scherer, Gabriella Allegri, Christineh N Sarkissian, et al.
Molecular Genetics and Metabolism|June 29, 2020
Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-upBarbara K Burton, Nicola Longo, Jerry Vockley, et al.
Molecular Genetics and Metabolism|April 10, 2018
Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trialCary O Harding, R Stephen Amato, Mary Stuy, et al.
Molecular Genetics and Metabolism|December 24, 2023
Long-term comparative effectiveness of pegvaliase versus medical nutrition therapy with and without sapropterin in adults with phenylketonuriaBarbara K Burton, Gillian E Clague, Cary O Harding, et al.
Molecular Genetics and Metabolism|September 17, 2017
Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2yearsSusan A Berry, Nicola Longo, George A Diaz, et al.
Orphanet Journal of Rare Diseases|June 20, 2025
Intelligence quotient scores among early-treated phenylketonuria patients: results from a systematic literature reviewFiona O'Sullivan, Ioannis Tomazos, Francjan J van Spronsen, et al.
Lancet (London, England)|April 19, 2014
Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trialNicola Longo, Cary O Harding, Barbara K Burton, et al.
Communications Biology|August 29, 2023
A G1528C Hadha knock-in mouse model recapitulates aspects of human clinical phenotypes for long-chain 3-hydroxyacyl-CoA dehydrogenase deficiencyGaren Gaston, Shannon Babcock, Renee Ryals, et al.
Ophthalmology|August 6, 2016
Characterization of Chorioretinopathy Associated with Mitochondrial Trifunctional Protein Disorders: Long-Term Follow-up of 21 CasesErin A Boese, Nieraj Jain, Yali Jia, et al.
Journal of Inherited Metabolic Disease|April 16, 2024
Early diagnosis and treatment by newborn screening (NBS) or family history is associated with improved visual outcomes for long-chain 3-hydroxyacylCoA dehydrogenase deficiency (LCHADD) chorioretinopathyMelanie B Gillingham, Dongseok Choi, Ashley Gregor, et al.
Pageof 12

Showing results (71-80 of 113) with videos related to

Sort By:
Pageof 12
Journal of Inherited Metabolic Disease|March 10, 2018
Tetrahydrobiopterin treatment reduces brain L-Phe but only partially improves serotonin in hyperphenylalaninemic ENU1/2 miceTanja Scherer, Gabriella Allegri, Christineh N Sarkissian, et al.
Molecular Genetics and Metabolism|June 29, 2020
Pegvaliase for the treatment of phenylketonuria: Results of the phase 2 dose-finding studies with long-term follow-upBarbara K Burton, Nicola Longo, Jerry Vockley, et al.
Molecular Genetics and Metabolism|April 10, 2018
Pegvaliase for the treatment of phenylketonuria: A pivotal, double-blind randomized discontinuation Phase 3 clinical trialCary O Harding, R Stephen Amato, Mary Stuy, et al.
Molecular Genetics and Metabolism|December 24, 2023
Long-term comparative effectiveness of pegvaliase versus medical nutrition therapy with and without sapropterin in adults with phenylketonuriaBarbara K Burton, Gillian E Clague, Cary O Harding, et al.
Molecular Genetics and Metabolism|September 17, 2017
Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2yearsSusan A Berry, Nicola Longo, George A Diaz, et al.
Orphanet Journal of Rare Diseases|June 20, 2025
Intelligence quotient scores among early-treated phenylketonuria patients: results from a systematic literature reviewFiona O'Sullivan, Ioannis Tomazos, Francjan J van Spronsen, et al.
Lancet (London, England)|April 19, 2014
Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trialNicola Longo, Cary O Harding, Barbara K Burton, et al.
Communications Biology|August 29, 2023
A G1528C Hadha knock-in mouse model recapitulates aspects of human clinical phenotypes for long-chain 3-hydroxyacyl-CoA dehydrogenase deficiencyGaren Gaston, Shannon Babcock, Renee Ryals, et al.
Ophthalmology|August 6, 2016
Characterization of Chorioretinopathy Associated with Mitochondrial Trifunctional Protein Disorders: Long-Term Follow-up of 21 CasesErin A Boese, Nieraj Jain, Yali Jia, et al.
Journal of Inherited Metabolic Disease|April 16, 2024
Early diagnosis and treatment by newborn screening (NBS) or family history is associated with improved visual outcomes for long-chain 3-hydroxyacylCoA dehydrogenase deficiency (LCHADD) chorioretinopathyMelanie B Gillingham, Dongseok Choi, Ashley Gregor, et al.
Pageof 12